AZD9496 First Time in Patients Ascending Dose Study
Status:
Completed
Trial end date:
2019-04-03
Target enrollment:
Participant gender:
Summary
This is a phase 1 open label multicentre study of AZD9496 administered orally in patients
with advanced ER+ HER2 negative breast cancer. The study design allows an escalation of dose
with intensive safety monitoring to ensure the safety of patients. The study will determine
the maximum tolerated dose. In addition, expansion cohort(s) at potential therapeutic dose(s)
in patients with or without ESR1 mutations will be enrolled to further determine the safety,
tolerability, pharmacokinetics and biological activity of AZD9496